Abstract
A patient who developed anti‐Cob in response to transfusion was studied. The antibody was a warm‐reactive, high‐titered, IgG alloantibody that did not fix complement, and reacted strongly in the antiglobulin phase. During a period of transfusion the patient developed a positive direct immunoglobulin test with anti‐Cob recoverable in the eluate. Reactions were stronger with enzyme‐treated red cells. Survival studies with 51Chromium‐labeled red cells showed: 1) normal survival of Co(b‐) red cells, and 2) accelerated destruction of Co(b+) red cells; initially, cells were destroyed with a one‐half disappearance time of 4 days, but after about 4 days, the rate of destruction increased. This study, together with reported suspected transfusion reactions attributed to anti‐Cob, suggest that anti‐Cob should be considered a clinically significant antibody.